Skip to main content
SpringerLink
Log in

Gefitinib/osimertinib

Development of resistance and transformation from pulmonary adenocarcinoma to large cell neuroendocrine lung carcinoma: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Ricordel C, et al. Large Cell Neuroendocrine Lung Carcinoma Transformation as an Acquired Resistance Mechanism to Osimertinib. Journal of Thoracic Oncology 12: e184-e186, No. 11, Nov 2017. Available from: URL: http://doi.org/10.1016/j.jtho.2017.07.019 - France

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gefitinib/osimertinib. Reactions Weekly 1681, 163 (2017). https://doi.org/10.1007/s40278-017-39439-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-017-39439-0

Search

Navigation